ClinicalTrials.Veeva

Menu

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study

Abbott logo

Abbott

Status

Completed

Conditions

Atrial Fibrillation

Treatments

Procedure: PVI + Lines ablation
Procedure: PVI
Procedure: PVI + CFE ablation

Study type

Interventional

Funder types

Industry

Identifiers

NCT01203748
AF-09-102-ID-AB

Details and patient eligibility

About

This investigation is designed with the hypothesis that combined PV Antral Isolation and Ablation of Complex Fractionated Electrograms (PVI+CFE) approach will offer a higher success rate compared to the Wide Circumferential Pulmonary Vein Antrum Isolation (PVI) approach and to the Combined PV Antral Isolation and Empiric Linear Ablation (PVI+Lines) approach.

Enrollment

589 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients age is18 years or greater;
  • Patients undergoing a first-time ablation procedure for AF;
  • Patients with persistent AF;
  • Persistent AF will be defined as a sustained episode lasting > 7 days and less than 3 years.
  • Patients with symptomatic AF that is refractory to at least one antiarrhythmic medication;
  • At least one episode of persistent AF must have been documented by ECG, holter, loop recorder, telemetry, trans telephonic monitoring (TTM), or implantable device within last 2 years of enrollment in this investigation;
  • Patients must be able and willing to provide written informed consent to participate in this investigation; and
  • Patients must be willing and able to comply with all peri-ablation and follow-up requirements.

Exclusion criteria

  • Patients with paroxysmal AF;
  • Patients with long-standing persistent AF;
  • Patients for whom cardioversion or sinus rhythm will never be attempted/pursued;
  • Patients with AF felt to be secondary to an obvious reversible cause;
  • Patients with contraindications to systemic anticoagulation with heparin or coumadin or a direct thrombin inhibitor;
  • Patients with left atrial size ≥ 60 mm (2D echocardiography, parasternal long axis view); and
  • Patients who are pregnant.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

589 participants in 3 patient groups

PVI + Lines Ablation
Experimental group
Treatment:
Procedure: PVI + Lines ablation
PVI Ablation
Active Comparator group
Treatment:
Procedure: PVI
PVI + CFE
Experimental group
Treatment:
Procedure: PVI + CFE ablation

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems